1naresh2naresh
Array ( [urn:ac.highwire.org:guest:identity] => Array ( [runtime-id] => urn:ac.highwire.org:guest:identity [type] => guest [service-id] => ajnr-ac.highwire.org [access-type] => Controlled [privilege] => Array ( [urn:ac.highwire.org:guest:privilege] => Array ( [runtime-id] => urn:ac.highwire.org:guest:privilege [type] => privilege-set [privilege-set] => GUEST ) ) [credentials] => Array ( [method] => guest ) ) [1f880afd-7258-4e15-b713-4599aa6e1ae9] => Array ( [runtime-id] => 1f880afd-7258-4e15-b713-4599aa6e1ae9 [type] => toll-free-key [service-id] => ajnr-ac.highwire.org [access-type] => Controlled [privilege] => Array ( [5cee10e8-8fc3-458e-bbc9-d0d12bf7e5fe] => Array ( [runtime-id] => 5cee10e8-8fc3-458e-bbc9-d0d12bf7e5fe [type] => toll-free-key ) ) [credentials] => Array ( [method] => toll-free-key [value] => tf_ipsecsha;d47f3f5554fa9c887ddc86ed607b86ab276d5dad ) ) ) 1naresh2nareshArray ( [urn:ac.highwire.org:guest:identity] => Array ( [runtime-id] => urn:ac.highwire.org:guest:identity [type] => guest [service-id] => ajnr-ac.highwire.org [access-type] => Controlled [privilege] => Array ( [urn:ac.highwire.org:guest:privilege] => Array ( [runtime-id] => urn:ac.highwire.org:guest:privilege [type] => privilege-set [privilege-set] => GUEST ) ) [credentials] => Array ( [method] => guest ) ) [1f880afd-7258-4e15-b713-4599aa6e1ae9] => Array ( [runtime-id] => 1f880afd-7258-4e15-b713-4599aa6e1ae9 [type] => toll-free-key [service-id] => ajnr-ac.highwire.org [access-type] => Controlled [privilege] => Array ( [5cee10e8-8fc3-458e-bbc9-d0d12bf7e5fe] => Array ( [runtime-id] => 5cee10e8-8fc3-458e-bbc9-d0d12bf7e5fe [type] => toll-free-key ) ) [credentials] => Array ( [method] => toll-free-key [value] => tf_ipsecsha;d47f3f5554fa9c887ddc86ed607b86ab276d5dad ) ) )Table 1:Demographic, clinical, and MR imaging—based measured brain characteristics of patients with MS used in the cross-sectional analysis*
PPMS SPMS RRMS No. (female-male) 20 (9:11) 14 (12:2) 30 (25:5) Mean age ± SD (yr) 52.5 ± 8.8 53.2 ± 11.7 39.8 ± 9.5 Mean disease duration ± SD (yr) 9.1 ± 5.34 16.9 ± 8.3 7.3 ± 6.6 EDSS (mean, median, range) 5.0, 6, 2–7.5 5.5, 6, 2–7.5 1.4, 1, 0–5 AI (mean, median, range) 3.2, 2, 0–8 3.4, 2.5, 1–8 0.54, 0, 0–2 BPF (mean ± SD) 0.84 ± 0.05 0.80 ± 0.05 0.87 ± 0.04 MOV (cm3, mean ± SD) 0.84 ± 0.12 0.78 ± 0.11 1.06 ± 0.18 Total CC area (cm2, mean ± SD) 566.3 ± 81.6 469.8 ± 89.0 566.1 ± 85.3 CC-segment 1 214.1 ± 30.2 189.9 ± 40.0 223.0 ± 39.0 CC-segment 2 66.2 ± 12.6 56.9 ± 9.2 67.0 ± 14.1 CC-segment 3 62.9 ± 10.8 49.3 ± 5.5 61.1 ± 13.2 CC-segment 4 51.5 ± 13.3 38.4 ± 9.2 48.8 ± 13.2 CC-segment 5 171.6 ± 32.1 135.4 ± 35.8 166.1 ± 29.2
Note:—PPMS indicates primary-progressive multiple sclerosis; SPMS, secondary-progressive multiple sclerosis; RRMS, relapsing-remitting multiple sclerosis; SD, standard deviation; EDSS, expanded disability status scale; AI, ambulation index; BPF, brain parenchymal fraction; CC, corpus callosum; MOV, medulla oblongata volume.
* The corpus collasum and MOV measurements are normalized as described in the “Materials and Methods” section.